52P - Expression of CT antigens in periampullary carcinomas patients: Potential minimally-invasive biomarkers for diagnosis

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Hepatobiliary Cancers
Translational Research
Presenter Shivam Singh
Citation Annals of Oncology (2016) 27 (suppl_9): ix9-ix18. 10.1093/annonc/mdw574
Authors S. Singh1, A. Saraya2, R. Sharma1
  • 1Biotechnology, Guru Gobind Singh Indraprastha University, 110078 - Delhi/IN
  • 2Gastroenterology, All India Institute of Medical Sciences, 110029 - Delhi/IN

Abstract

Background

Detection of periampullary carcinoma (PAC) by modern diagnostic techniques is less promising. Cancer Testis Antigens (CTAs) are found to be expressed by normal germ cells only. Recent studies showed aberrant expression of certain CTAs viz. Sp17, NY-ESO-1, SCP1 and GAGE in various cancers. However, their expression have not yet been analysed in PAC.

Methods

Real time PCR was done to assess the mRNA expression of Sp17, NY-ESO-1, SCP1 and GAGE in tissues and sera samples collected from consented PAC patients and normal subjects. Moreover, circulating levels of anti-Sp17 and NY-ESO-1 antibodies were determined in sera of PAC patients and normal subjects using ELISA. Immunohistochemical analysis of Sp17 protein in PAC tissues was also carried out.

Results

Significantly increased mRNA expression of Sp17, NY-ESO-1, SCP1 and GAGE was found in 70%, 75%, 80% and 70%, respectively, PAC tissues when compared with distant matched non-malignant tissues (P 

Conclusions

In the present study, increased expression of all the CTA genes was observed in both tissues and sera of PAC patients emphasizing its diagnostic potential. Moreover, elevated circulating levels of anti-Sp-17 and NY-ESO-1 antibodies were observed in serum of PAC patients with good sensitivity and specificity and could discriminate these patients from healthy individuals. In addition to these, expression of Sp17 protein in PAC tissues confirms the high circulating levels of anti-Sp17 antibody in serum of PAC patients.

Clinical trial indentification

Legal entity responsible for the study

Dr Rinu Sharma (Principal Investigator)

Funding

Department of Science of Technology, India

Disclosure

All authors have declared no conflicts of interest.